NEW YORK (GenomeWeb News) – Quidel has received US Food and Drug Administration 510(k) clearance to market its molecular respiratory viral panel in the US, the company said on Tuesday.

The assay, called the Quidel Molecular RSV + hMPV assay, detects respiratory syncytial virus and human metapneumovirus and distinguishes the two from each other. While they are different viruses, they cause respiratory infections with very similar symptoms, Quidel said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: The sea anemone is sequenced, a team describes a CRISPR/Cas9-based approach to label specific sites in the genome, and more. 

In a short video, CNN introduces viewers to a fecal transplant poop donor and explains how the treatments are made.

Researchers are testing the use of transgenically altered diamondback moths as an alternative to pesticides in controlling the bugs.

Two recent papers published in Science and Nature Medicine describe work that may result in a universal vaccine for the flu.